The Latest
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit Of ORPATHYS® Plus TAGRISSO® In Treatment-Naïve Patients With MET-Overexpressing EGFR-mutated Lung Cancer In China
HUTCHMED announces trial results showing notable progression-free survival benefits with ORPATHYS® plus TAGRISSO® in lung cancer patients in China.